Data gathered: August 2
AI Stock Analysis - Tarsus Pharmaceuticals (TARS)
Analysis generated March 23, 2025. Powered by Chat GPT.
Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative treatments for ophthalmic conditions. Their portfolio includes a robust pipeline of novel therapeutic candidates, with an emphasis on addressing unmet needs in eye care. Their focus on ocular conditions creates a niche market where they can leverage their scientific expertise and cutting-edge technology.
Stock Alerts - Tarsus Pharmaceuticals (TARS)
 |
Tarsus Pharmaceuticals | July 18 Price is up by 7.5% in the last 24h. |
|
Tarsus Pharmaceuticals | June 19 Insider Alert: Farrow Jeffrey S is selling shares |
|
Tarsus Pharmaceuticals | June 18 Insider Alert: Lin Elizabeth Yeu is selling shares |
|
Tarsus Pharmaceuticals | June 10 Employee Rating is up by 4.7% over the last month. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Tarsus Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 21 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 12,000 | Sign up | Sign up | Sign up |
| Employee Rating | 90 | Sign up | Sign up | Sign up |
| Google Trends | 18 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 37 | Sign up | Sign up | Sign up |
| Facebook Followers | 509 | Sign up | Sign up | Sign up |
| Instagram Followers | 1,207 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 13 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 843 | Sign up | Sign up | Sign up |
| Twitter Followers | 625 | Sign up | Sign up | Sign up |
| Twitter Mentions | 11 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 100 | Sign up | Sign up | Sign up |
| Linkedin Employees | 366 | Sign up | Sign up | Sign up |
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States.
| Price | $40.81 |
| Target Price | Sign up |
| Volume | 1,050,000 |
| Market Cap | $1.63B |
| Year Range | $38.82 - $56.94 |
| Dividend Yield | 0% |
| Analyst Rating | 86% buy |
| Earnings Date | August 6 '25 |
| Industry | Biotechnology |
In the news
 |
Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Path To ProfitabilityJuly 23 - Yahoo |
 |
Arizona State Retirement System Buys 470 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)July 23 - ETF Daily News |
|
William Blair Has Bearish Forecast for TARS Q2 EarningsJuly 17 - ETF Daily News |
|
What is William Blair’s Estimate for TARS FY2026 Earnings?July 17 - ETF Daily News |
Tarsus Pharmaceuticals: Making Big StridesJuly 16 - SeekingAlpha |
|
|
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of “Buy” by AnalystsJuly 11 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 78M | 5.2M | 73M | -25M | -26M | -0.640 |
| Q4 '24 | 66M | 4.9M | 61M | -23M | -20M | -0.600 |
| Q3 '24 | 48M | 3.2M | 45M | -23M | -21M | -0.610 |
| Q2 '24 | 41M | 3M | 38M | -33M | -31M | -0.880 |
| Q1 '24 | 28M | 1.7M | 26M | -36M | -34M | -1.010 |
Insider Transactions View All
| Farrow Jeffrey S filed to sell 36,704 shares at $40.4. June 18 '25 |
| Lin Elizabeth Yeu filed to sell 7,694 shares at $41.1. June 17 '25 |
| Mottiwala Aziz filed to sell 47,557 shares at $43.8. June 11 '25 |
| Azamian Bobak R. filed to sell 824,106 shares at $50. March 26 '25 |
| Farrow Jeffrey S filed to sell 22,431 shares at $50.1. March 20 '25 |
Similar companies
Read more about Tarsus Pharmaceuticals (TARS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Tarsus Pharmaceuticals?
The Market Cap of Tarsus Pharmaceuticals is $1.63B.
When does Tarsus Pharmaceuticals report earnings?
Tarsus Pharmaceuticals will report its next earnings on August 6 '25.
What is the current stock price of Tarsus Pharmaceuticals?
Currently, the price of one share of Tarsus Pharmaceuticals stock is $40.81.
How can I analyze the TARS stock price chart for investment decisions?
The TARS stock price chart above provides a comprehensive visual representation of Tarsus Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Tarsus Pharmaceuticals shares. Our platform offers an up-to-date TARS stock price chart, along with technical data analysis and alternative data insights.
Does TARS offer dividends to its shareholders?
As of our latest update, Tarsus Pharmaceuticals (TARS) does not offer dividends to its shareholders. Investors interested in Tarsus Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Tarsus Pharmaceuticals?
Some of the similar stocks of Tarsus Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.